Memantina Flas Combix (Memantine Hydrochloride)

• Memantina Flas Combix is a NMDA receptor antagonist used in the management of Alzheimer’s disease.
• Alzheimer’s disease (moderate to severe): improves cognition and functional abilities in patients with moderate to severe disease.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel, it blocks excessive calcium influx caused by glutamate over‑activation, thereby reducing excitotoxic neuronal injury that contributes to cognitive decline in Alzheimer’s disease.

Memantina Flas Combix may be associated with several adverse reactions.

Common Side Effects

• Dizziness: transient light‑headedness, especially at treatment initiation.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Constipation: reduced bowel movements, manageable with diet.
• Confusion: occasional disorientation, typically reversible.
• Hypertension: modest increase in blood pressure in some patients.
• Somnolence: mild sleepiness, may improve over time.

Serious or Rare Side Effects

• Seizures: rare occurrence, requires immediate medical attention.
• Severe allergic reactions: rash, swelling, or anaphylaxis.
• Hallucinations or psychosis: uncommon but serious neuropsychiatric events.
• Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.
• Suicidal thoughts: rare but necessitates prompt evaluation.
• Stevens‑Johnson syndrome: severe skin reaction, requires discontinuation.

• When prescribing Memantina Flas Combix, clinicians should consider several safety aspects.
• Renal impairment: adjust dose or monitor renal function closely.
• Hepatic impairment: use with caution and monitor liver enzymes.
• History of seizures: monitor for increased seizure activity.
• Concomitant NMDA agonists: avoid combined use to prevent antagonistic effects.
• Pregnancy and lactation: safety not established; weigh benefits against potential risks.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Memantina Flas Combix can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

• Amantadine: additive neurotoxic risk, may exacerbate CNS side effects.
• Other NMDA antagonists: combined effect can increase toxicity.
• Strong CYP450 inhibitors (e.g., ketoconazole): may raise memantine plasma levels.

Moderate Interactions (Monitor Closely)

• Anticholinesterase inhibitors (e.g., donepezil): may reduce overall efficacy.
• Diuretics: potential for increased hypotension.
• Antihypertensive agents: monitor blood pressure for additive lowering effect.